---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029069"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:56:21.851724+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech clarifies Q2 sales per facility grew YoY but declined QoQ

## Summary
- On Aug 15, 2023 earnings call, Sanara MedTech said sales per facility were growing; today's 8-K clarifies it was YoY, not QoQ.
- Sequentially (Q2 2023 vs Q1 2023), sales per facility slightly declined.
- Metric calculated as monthly Surgical Products sales divided by number of facilities with revenue; quarterly is average of monthly.
- Surgical Products include CellerateRX, FORTIFY TRG, FORTIFY FLOWABLE, TEXAGEN, BiFORM, AMPLIFY, ALLOCYTE.
- Correction filed under Regulation FD to avoid misleading investors.

## SEC filing metadata
- accession: 0001493152-23-029069
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/0001493152-23-029069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029069
- JSON: https://secwatch.observer/filing/0001493152-23-029069.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.